allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq (tregzi)
allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq is an FDA-licensed reference biologic from Orca Biosystems Inc..
Reference product
tregzi allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq
Orca Biosystems Inc.
View full reference-product record- Approved
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Reference approval
Approval date of the reference allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq product.
3 mo ago
allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Go beyond the database.
Try Assyro Intelligence for your regulatory research. Ready to discuss your team’s workflow? Book a demo.